Company Overview and News

1
VICL / Vical Inc. 10-Q (Quarterly Report)

2018-08-07 sec.gov - 1
vicl-10q_20180630.htm UNITED STATES
VICL

 
Vical (VICL) Reports Q2 Loss, Tops Revenue Estimates

2018-08-07 zacks
Vical (VICL - Free Report) just came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.30 per share a year ago. These figures are adjusted for non-recurring items.
AMT NHI VICL BCRX GTLS

 
Vical Reports Second Quarter 2018 Financial and Operational Results

2018-08-07 globenewswire
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months ended June 30, 2018. Net loss for the second quarter of 2018 was $4.9 million, or $0.22 per share, compared with a net loss of $3.3 million, or $0.30 per share, for the second quarter of 2017. Revenues for the second quarter of 2018 were $0.7 million, compared with revenues of $3.
4503 ALPMY ALPMF VICL

 
VICL / Vical Inc. FORM 8-K (Current Report)

2018-08-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
VICL

 
Vical Looking For Strategic Options - Is There Any Hope?

2018-07-24 seekingalpha
Vical announced that it would pursue strategic options to boost shareholder value in the coming months.
VICL

 
Vical Announces Review of Potential Strategic Transactions

2018-07-19 globenewswire
SAN DIEGO, July 19, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that its Board of Directors plans to explore a range of strategic options to enhance shareholder value. The company has retained MTS Health Partners, L.P. as its financial advisor to assist in the strategic review process.
VICL

 
VICL / Vical Inc. / ARMISTICE CAPITAL, LLC - null (Passive Investment)

2018-07-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
VICL

1
VICL / Vical Inc. / ARMISTICE CAPITAL, LLC - null (Passive Investment)

2018-07-06 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
VICL

482
Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha - 4
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP

8
Vical: No Compelling Reason To Buy

2018-06-12 seekingalpha - 1
Cash on hand is sufficient to fund operations into 2019 and plans to raise an additional $40 million that extend the runway into 2020.
4503 ALPMY ALPMF VICL

9
Vical Becomes An Attractive Speculative Play After Latest Clinical Trial Blunder

2018-06-12 seekingalpha - 2
Vical announced the failure of a phase 2 study treating patients with the herpes simplex virus type 2.
4503 ALPMY ALPMF VICL

36
Vical's stock plunges 23% premarket after genital herpes treatment fails in phase 2 trial

2018-06-11 marketwatch - 1
Vical Inc. said Monday a phase 2 trial of its treatment for genital herpes failed to meet its primary endpoint of annualized lesion recurrence rate. The stock was still inactive in premarket trade. In a study of 261 healthy adults with herpes simplex virus type 2, aged 18 to 50, with a self-reported history of 4 to 9 recurrences a year, Vical said the annualized recurrence rate in the placebo group was "far less" than what was expected, meaning there was "significantly less power" to show a vaccine effect in the trial.
ARE CYORP ICFI WIRE MBUU CIO GNCA SNDX VICL

4
VICL / Vical Inc. FORM 8-K (Current Report)

2018-06-11 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 8-K _____________________ CURRENT REPORT
VICL

3
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint

2018-06-11 globenewswire
SAN DIEGO, June 11, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced top-line results from a randomized, double-blind, placebo-controlled, Phase 2 clinical study of its therapeutic bivalent vaccine candidate for herpes simplex virus type 2 (HSV-2), the leading cause of recurrent genital herpes. The study did not meet its primary endpoint of annualized lesion recurrence rate calculated based on those genital recurrences that were both clinically- and virologically-confirmed during a minimum of nine months of surveillance.
VICL

5
VICL / Vical Inc. FORM 8-K (Current Report)

2018-06-07 sec.gov - 2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
VICL

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to VICL / Vical Inc. on message board site Silicon Investor.

VICL (Vical Labs) VICL (Vical Labs) VICL (Vical Labs) Vical Vical Vical
CUSIP: 925602104